Heart failure associated with ustekinumab therapy for treatment of Crohn's Disease

被引:1
|
作者
Morgenweck, Erica [1 ]
Park, Brian [1 ]
Bower, Richard [1 ]
机构
[1] Naval Med Ctr San Diego, Gastroenterol, San Diego, CA 92134 USA
关键词
Gastrointestinal system; Crohn's disease; Heart failure; MAINTENANCE THERAPY; CARDIOMYOPATHY; INDUCTION;
D O I
10.1136/bcr-2022-250376
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A man in his 60s with penetrating ileocolonic Crohn's disease (CD), recently started on ustekinumab therapy, presented with new onset dyspnoea, paroxysmal nocturnal dyspnoea and dependent oedema. He was diagnosed with heart failure (HF) 10 months after starting ustekinumab therapy. His symptoms resolved with discontinuation of ustekinumab and he had recovery of his cardiac function. Though initial studies that led to the U.S Food and Drug Administration (FDA)approval for ustekinumab did not detect a signal for HF, postmarketing surveillance has detected rare cases of HF after initiation of the medication. This is one of the few reported cases of HF associated with ustekinumab therapy for CD.
引用
收藏
页数:3
相关论文
共 50 条
  • [21] An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients
    Kawalec, Pawel
    Mocko, Pawel
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2018, 7 (02) : 101 - 111
  • [22] Ustekinumab as Effective Treatment for Refractory Amicrobial Pustulosis of the Folds Associated with Crohn's Disease
    Al-Raddadi, Reem
    Frances, Camille
    Moguelet, Philippe
    Bachmeyer, Claude
    Guegan, Sarah
    ACTA DERMATO-VENEREOLOGICA, 2017, 97 (03) : 389 - 390
  • [23] Ustekinumab treatment for neutrophilic dermatoses associated with Crohn's disease: A multicenter retrospective study
    de Risi-Pugliese, Tullia
    Seksik, Philippe
    Bouaziz, Jean-David
    Chasset, Francois
    Moguelet, Philippe
    Gornet, Jean-Marc
    Bourrier, Anne
    Amiot, Aurelien
    Beaugerie, Laurent
    Frances, Camille
    Guegan, Sarah
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (03) : 781 - 784
  • [24] Ustekinumab in Crohn's disease: evidence to date and place in therapy
    Engel, Tal
    Kopylov, Uri
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2016, 7 (04) : 208 - 214
  • [25] DUAL TARGETED THERAPY WITH USTEKINUMAB AND UPADACITINIB IN CROHN'S DISEASE
    Miyatani, Yusuke
    Choi, David
    Zinger, Adar
    Rubin, David T.
    GASTROENTEROLOGY, 2023, 164 (06) : S1128 - S1128
  • [26] Efficacy of Ustekinumab Therapy in Patients With Perianal Crohn's Disease
    Manski, Scott
    Dioguardi, Vincent
    Weil, Blake J.
    Edirisuriya, Chelsea
    Gandhi, Hema K.
    Shivashankar, Raina
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S847 - S847
  • [27] Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
    Sandborn, William J.
    Gasink, Christopher
    Gao, Long-Long
    Blank, Marion A.
    Johanns, Jewel
    Guzzo, Cynthia
    Sands, Bruce E.
    Hanauer, Stephen B.
    Targan, Stephan
    Rutgeerts, Paul
    Ghosh, Subrata
    de Villiers, Willem J. S.
    Panaccione, Remo
    Greenberg, Gordon
    Schreiber, Stefan
    Lichtiger, Simon
    Feagan, Brian G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (16): : 1519 - 1528
  • [28] Malignant melanoma during ustekinumab therapy of Crohn's disease
    Ehmann, Laura M.
    Tillack-Schreiber, Cornelia
    Brand, Stephan
    Wollenberg, Andreas
    INFLAMMATORY BOWEL DISEASES, 2012, 18 (01) : E199 - E200
  • [29] Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients
    Doherty, Matthew K.
    Ding, Tao
    Koumpouras, Charlie
    Telesco, Shannon E.
    Monast, Calixte
    Das, Anuk
    Brodmerkel, Carrie
    Schloss, Patrick D.
    MBIO, 2018, 9 (02):
  • [30] Predictors of Ustekinumab Failure in Crohn's Disease After Dose Intensification
    Dalal, Rahul S.
    Njie, Cheikh
    Marcus, Jenna
    Gupta, Sanchit
    Allegretti, Jessica R.
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (08) : 1294 - 1301